



DRUGS AND CHEMICALS LIMITED

Registered Office :  
815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA).  
Ph. : +91-265-2991021 / 2991022

Email : admin@pardrugs.com

CIN No. : L24117GJ1999PLC035512

[www.pardrugs.com](http://www.pardrugs.com)

PAR/CS/NSE/2022-23/45

To,  
The Manager  
Listing department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051  
Maharashtra

**Date: 12/11/2022**

**Symbol - PAR, ISIN: INE04LG01015**

Subject: Investors Presentation

Ref.: Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to above captioned subject and pursuant Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby attached our latest Investors Presentation.

You are requested to kindly take note on your record.

Yours Faithfully

**For PAR DRUGS AND CHEMICALS LIMITED**

---

**(Mr. Falgun V. Savani)**

**Managing Director**

**DIN: 00198236**

Encl: As above



Q2/H1-FY23 Earnings Presentation

# Company Overview




# Company Overview




- Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs.
- The Company today manufactures 25 different products and all the requisite grades as available in the market. The product portfolio presently comprises of 15 APIs and 10 Fine Chemicals which are marketed domestically and exported.
- Currently, the company owns and operates a manufacturing facility at Bhavnagar in Gujarat with an annual capacity of 9,700 MT.
- The company is the largest manufacturer of Magnesium Hydroxide, Sucralfate and Magnesium Trisilicate in India.
- Company's key customers include Essential Drugs Company Ltd., Pfizer Ltd., United Phosphorus Ltd., Cipla Ltd., etc.
- PDCL exports its products to approximately 16 countries, including Germany, the United Kingdom, Bangladesh, Iran, and U.A.E etc.
- APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

## Operational Revenues (INR Mn)



## Business Mix (Q2-FY23)





**Diversified Portfolio:** The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 15 APIs and 10 Fine Chemicals which are marketed domestically and exported.



**Global Presence:** The Company is operating both in domestic and export markets. The export products are to approximately 16 countries, including Germany, United Kingdom, Bangladesh, Iran, and U.A.E, Indonesia, Japan, South Korea, etc.



**Experienced Promoters:** Led by qualified and experienced Promoters and key managerial personnel, who we believe have extensive knowledge and understanding of the APIs business environment and have the expertise and vision to organically scale up the business.



**Robust Chemistry Capabilities:** A research driven Company with R&D efforts focused on developing processes and achieving process improvements and production cost efficiencies.



**Diversified Customer base:** Catering to more than 241 customers through dealers/agents worldwide.



**Established Sales and distribution network:** Comprising of more than 40 dealers and distribution network is spread globally comprising of 13 agents.



**Cash Rich Company:** The company is a net debt free and generates free cash flow. They plan its expansions through internal accruals.

The image features a background of financial documents with a bar chart, a pie chart, and a pair of glasses. A large blue circle on the left contains the text 'FINANCIAL & OPERATIONAL HIGHLIGHTS'. A yellow circle is positioned above the blue one. The bar chart shows monthly data from February to December with values ranging from 10.85 to 31.08. The pie chart shows segments with values 29 and 22.

# FINANCIAL & OPERATIONAL HIGHLIGHTS



## Q2-FY23 Financial Highlights


Revenue <b>INR 248 Mn</b>	EBITDA <b>INR 59 Mn</b>	EBITDA Margin <b>23.79%</b>
PAT <b>INR 37 Mn</b>	PAT Margin <b>14.92%</b>	Diluted EPS <b>INR 3.03</b>

## H1-FY23 Financial Highlights

Revenue <b>INR 483 Mn</b>	EBITDA <b>INR 95 Mn</b>	EBITDA Margin <b>19.66%</b>
PAT <b>INR 60 Mn</b>	PAT Margin <b>12.42%</b>	Diluted EPS <b>INR 4.89</b>

## Operational Highlights

- Sales growth in the domestic market was 42% whereas on the export market front it was at around 11%.
- There has been an increase in sales of higher margin products without compromising sales of lower profit margin items.
- Company is working on restructuring and debottlenecking of the old plant to enhance the quality and ease of working and thereby increase the production capacity.



Q2/H1-FY23  
Financial  
Overview





# Quarterly Income Statement (IND-AS)

Income Statement (INR Mn)	Q2-FY23	Q2-FY22	Y-o-Y	Q1-FY23	Q-o-Q
Income from Operations	248	196	26.5%	235	5.5%
Total Expenses	189	156	21.2%	198	(4.5)%
<b>EBITDA</b>	<b>59</b>	<b>40</b>	<b>47.5%</b>	<b>37</b>	<b>59.5%</b>
<i>EBITDA Margins (%)</i>	<i>23.79%</i>	<i>20.41%</i>	<i>338 Bps</i>	<i>15.74%</i>	<i>805 Bps</i>
Finance Cost	0	2	NA	1	NA
Depreciation	9	8	12.5%	7	28.6%
Other Income	0	0	NA	2	NA
<b>Profit Before Tax</b>	<b>50</b>	<b>30</b>	<b>66.7%</b>	<b>31</b>	<b>61.3%</b>
Tax	13	8	62.5%	8	62.5%
<b>Profit after tax</b>	<b>37</b>	<b>22</b>	<b>68.2%</b>	<b>23</b>	<b>60.9%</b>
<i>PAT Margins (%)</i>	<i>14.92%</i>	<i>11.22%</i>	<i>370 Bps</i>	<i>9.79%</i>	<i>513 Bps</i>
Diluted EPS (INR)	3.03	1.80	68.3%	1.86	62.9%

# Half-Yearly Income Statement (IND-AS)

Income Statement (INR Mn)	H1-FY23	H1-FY22	Y-o-Y
Income from Operations	483	361	33.8%
Total Expenses	388	280	38.6%
<b>EBITDA</b>	<b>95</b>	<b>81</b>	<b>17.3%</b>
<i>EBITDA Margins(%)</i>	<i>19.66%</i>	<i>22.44%</i>	<i>(278) Bps</i>
Finance Cost	1	3	(66.7)%
Depreciation	16	16	NA
Other Income	2	1	NA
<b>Profit Before Tax</b>	<b>80</b>	<b>63</b>	<b>27.0%</b>
Tax	20	16	25.0%
<b>Profit after tax</b>	<b>60</b>	<b>47</b>	<b>27.7%</b>
<i>PAT Margins (%)</i>	<i>12.42%</i>	<i>13.02%</i>	<i>(60) Bps</i>
Diluted EPS (INR)	4.89	3.80	28.7%


# Historical Income Statement

Income Statement (INR Mn)	FY20	FY21	FY22	H1-FY23
<b>Income from Operations</b>	<b>558</b>	<b>608</b>	<b>751</b>	<b>483</b>
Total Expenses	464	447	588	388
<b>EBITDA</b>	<b>94</b>	<b>161</b>	<b>163</b>	<b>95</b>
<i>EBITDA Margins (%)</i>	<i>16.85%</i>	<i>26.48%</i>	<i>21.70%</i>	<i>19.66%</i>
Finance Cost	8	7	5	1
Depreciation	27	28	33	16
Other Income	1	2	2	2
<b>Profit before Extra Ordinary Items</b>	<b>60</b>	<b>128</b>	<b>127</b>	<b>80</b>
Extraordinary items	-	(19)	-	-
<b>Profit Before Tax</b>	<b>60</b>	<b>147</b>	<b>127</b>	<b>80</b>
Tax	12	31	35	20
<b>Profit after tax</b>	<b>48</b>	<b>116</b>	<b>92</b>	<b>60</b>
<i>PAT Margins (%)</i>	<i>8.60%</i>	<i>19.08%</i>	<i>12.25%</i>	<i>12.42%</i>
Diluted EPS (INR)	7.75	18.87	7.49	4.89


# Balance Sheet

EQUITIES & LIABILITIES (INR Mn)	FY21	FY22	H1-FY23	ASSETS (INR Mn)	FY21	FY22	H1-FY23
<b>Shareholder Funds</b>	<b>522</b>	<b>599</b>	<b>659</b>	<b>Non Current Assets</b>	<b>352</b>	<b>351</b>	<b>363</b>
(A) Equity Share Capital	61	123	123	(A) Fixed Assets	-	-	-
(B) Reserves & Surplus	461	476	536	(i) Tangible Assets	299	341	331
				(ii) Capital work-in-progress	45	2	24
<b>Non-current Liabilities</b>	<b>82</b>	<b>39</b>	<b>40</b>	(B) Non Current Investments	-	-	-
(A) Long Term borrowings	44	-	-	(C) Other Non Current Assets	8	8	8
(B) Deferred Tax Liabilities (net)	34	35	35				
(C) Long term Provisions	4	4	5				
<b>Current Liabilities</b>	<b>160</b>	<b>149</b>	<b>150</b>	<b>Current Assets</b>	<b>412</b>	<b>436</b>	<b>486</b>
(A) Short term borrowings	32	-	36	(A) Inventories	30	47	45
(B) Trade Payables	67	107	79	(B) Trade Receivables	125	185	222
(C) Other Current Liabilities	25	8	15	(C) Cash & cash equivalents	212	163	194
(D) Short term Provisions	36	34	20	(D) Short Term Loans & Advances	0	0	0
				(E) Other Current Assets	45	41	25
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	<b>764</b>	<b>787</b>	<b>849</b>	<b>GRAND TOTAL – ASSETS</b>	<b>764</b>	<b>787</b>	<b>849</b>


### Operational Revenue (INR Mn)




### EBITDA (INR Mn) & EBITDA Margins (%)




### PAT (INR Mn) & PAT Margins (%)




### RoCE & RoE




### Net Debt to Equity Ratio (x)



### Net Worth (INR Mn)



## Stock Market Performance (as on 30th September, 2022)




### Price Data (30<sup>th</sup> September, 2022)

INR

Face Value	10.0
Market Price	151.5
52 Week High/Low	310.6/131.7
Market Cap (Mn)	1,846.0
Equity Shares Outstanding (Mn)	12.3
1 Year Avg Trading Volume ('000)	26.1

### Shareholding Pattern as on 30<sup>th</sup> September, 2022



**Par Drugs and Chemicals Limited:**

The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from, this Presentation is expressly excluded. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigation etc may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forward-looking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision.

**Valorem Advisors Disclaimer:**

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

**For further details, please feel free to contact our Investor Relations Representatives:**



Mr. Anuj Sonpal

Valorem Advisors

Tel: +91-22-4903-9500

Email: [pardrugs@valoremadvisors.com](mailto:pardrugs@valoremadvisors.com)



Thank  
You